Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


China Medical City To Acquire Korean Biotechnology

This article was originally published in PharmAsia News

Executive Summary

Six Korean R&D institutions and eight companies in biopharmaceuticals recently signed MOUs for 16 programs with China Medical City in Jiangsu province. The Daejeon City representatives from Korea will be introducing world-class new drug R&D technologies into China, as well as the industrialization and production of health care and pharmaceutical products. Since its establishment, China Medical City has been targeting Korean investors. Last year, it signed an agreement with its counterpart to set up a center that offers collaborative biopharmaceutical services to Korean enterprises operating in the medical city. (Click here for more - Chinese Language)



Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts